reference/425298

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/425298

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	29
issn	0030-2414 1423-0232
issueIdentifier	1
pageRange	25-29
publicationName	Oncology
startingPage	25
bibliographicCitation	Vansteenkiste J, Ramlau R, von Pawel J, San Antonio B, Eschbach C, Szczesna A, Kennedy L, Visseren-Grul C, Chouaki N, Reck M. A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer. Oncology. 2012;82(1):25–9. doi: 10.1159/000335268. PMID: 22269428.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87c3ef7945da1838a811172058399109 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_21139612236dbf758b8868933a8a205c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4db3d8face506c2bd5b28f6ec34a5631 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e274f14feb534ccdef1441aaea822c2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d861514468fedba5fc2b2c1bc8aee7db http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4ef24ff2bb40b4428b4ea6bdd20c8426 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a0a9efeff75ed6cca3037e2af0a2a6d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1be0efb2371d48844e539ee12c13b77 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b02a4ff15aa1b72804b483501f52458 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f29112ac2f9c74d3c48ca9a03b24d5e1
date	2012
identifier	https://pubmed.ncbi.nlm.nih.gov/22269428 https://doi.org/10.1159/000335268
isPartOf	https://portal.issn.org/resource/ISSN/1423-0232 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/6265 https://portal.issn.org/resource/ISSN/0030-2414
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer
discusses	http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0016932 http://id.nlm.nih.gov/mesh/M0490995 http://id.nlm.nih.gov/mesh/M0004505 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0011238
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D002945Q000008 http://id.nlm.nih.gov/mesh/D007211Q000008 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D005971Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D010919 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006147Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3d628a25e892b9935143372f9882c544 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5792807d3e9e12df929850eb909e1bdf http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fe0d872c4ea3e7d9f07488fc82841cc8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176167 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_472b28cee6c37ce9d58de4aa1dc6d7ef http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245741053 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128132375 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837

Total number of triples: 64.